Med-IQ CME: ATTR-CM at ACC.26: New Evidence, Evolving Strategies
This educational activity reviews emerging clinical evidence and evolving treatment strategies for transthyretin amyloid cardiomyopathy (ATTR-CM), with a focus on recently approved disease-modifying therapies. Learners will examine key clinical trial data related to efficacy, safety, quality of life, functional outcomes, and long-term disease stabilization, as well as explore how these findings may be applied in patient scenarios representative of contemporary clinical practice.
Cost: Free
View Offer chevron_rightKey Features
Stay current on the rapidly evolving ATTR-CM treatment landscape with a review of newly approved disease-modifying therapies, pivotal clinical trial data, and practical patient cases designed to help clinicians apply the latest evidence in practice.
Topics Covered
Emerging evidence and evolving treatment strategies for ATTR-CM, including new therapies, clinical trial outcomes, and real-world patient management.
Learning Objectives
Upon completion, participants should be able to:
- Discuss clinical trial data regarding the efficacy and safety of agents recently approved for the treatment of ATTR-CM
- Incorporate agents recently approved for the treatment of ATTR-CM into patient scenarios representative of clinical practice
Target Audience
This activity is intended for physicians and advanced practice providers.
Additional credit info
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
Other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.